Adaptimmune Therapeutics Surpasses Q1 2025 Earnings Expectations with Optimistic TECELRA Sales Forecast
Adaptimmune Therapeutics Plc’s Q1 2025 earnings exceeded expectations, with the company anticipating $35-45 million in TECELRA sales and positioning itself as a key player in the fight against cancer.
- Adaptimmune Therapeutics Plc
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- AI generated
3 minutes to read